Metabolic Health

FDA Approves Two New Weight Loss Drugs Foundayo and Zepbound for Obesity

The FDA recently approved two new medications for chronic weight management: Foundayo (orforglipron) on April 2, 2026, and Zepbound (tirzepatide) injection within the past two weeks. Both drugs are indicated for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol. These medications must be used alongside a reduced-calorie diet and increased physical activity. The approvals represent significant additions to the growing arsenal of FDA-approved weight management therapies, potentially offering new options for millions of Americans struggling with obesity and related metabolic conditions.